Form 4: Director Shlomo Yanai Executes Amneal Stock Transactions

Amneal Pharmaceuticals director Shlomo Yanai acquired 34,819 shares through the vesting of restricted stock units and was granted 19,824 new units.

Summary

• Director Shlomo Yanai exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock.
• Following the transaction, the director's total beneficial ownership of Class A Common Stock increased to 320,804 shares.
• The director was also granted 19,824 new restricted stock units on May 6, 2026, which are subject to future vesting conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation and equity vesting rather than a strategic shift or market-moving event.

Positives

• Director maintains a significant equity stake of 320,804 shares in the company.
• The acquisition of shares through RSU vesting aligns the director's interests with those of shareholders.

Negatives

• None identified; this is a standard compensatory equity transaction.

Risks

• Future vesting of the newly granted 19,824 RSUs is contingent upon meeting specific time-based conditions.

Future Outlook

The newly granted 19,824 RSUs will vest on the later of the day preceding the first annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that this filing represents routine equity-based compensation for corporate directors, which is standard practice within the pharmaceutical industry to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of RSU-based compensation is consistent with standard governance practices at peer pharmaceutical companies like Teva, Viatris, and Perrigo.
• The vesting schedule aligns with typical industry benchmarks for non-employee director equity grants.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Vesting of the 19,824 newly granted restricted stock units based on the company's annual meeting schedule.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Form 4, Insider Trading, Director Compensation, Restricted Stock Units